Combined therapy with intravenous recombinant tissue plasminogen activator (rt-PA) and edaravone in the acute ischemic stroke patients within 3 hours of onset

Combined therapy with intravenous recombinant tissue plasminogen activator (rt-PA) and edaravone in the acute ischemic stroke patients within 3 hours of onset - Combined therapy with intravenous recombinant tissue plasminogen activator (rt-PA) and edaravone in the acute ischemic stroke patients within 3 hours of onset

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002512

Enrollment

100

Registered

2009-12-01

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iscemic stroke

Interventions

Group A:Start of edaravone administration within 15 minutes after starting IV rt-PA A single alteplase(rt-PA) dose of 0.6 mg/kg is administered intravenously, with 10% given as a bolus, followed b

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients within 3 hours of onset time 2)Arterial lesion of anterior circulation on magnetic resonance angiography

Exclusion criteria

Exclusion criteria: 1)Diffusion weighted imaging evidence of significant early ischemic change 2)Other exclusion criteria are same as Japan Alteplase Clinical Trial (J-ACT) (stroke 2006;37:1810) 3)exclusion criteria of edaravone administraion mentioned in the package insert. Serume creatinine concentration over 1.5mg/dl

Design outcomes

Primary

Measure	Time frame
Clinical improvement Hemorrhagic complication	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026